AU2018346681B2 - Regulatory T cell epitopes - Google Patents

Regulatory T cell epitopes Download PDF

Info

Publication number
AU2018346681B2
AU2018346681B2 AU2018346681A AU2018346681A AU2018346681B2 AU 2018346681 B2 AU2018346681 B2 AU 2018346681B2 AU 2018346681 A AU2018346681 A AU 2018346681A AU 2018346681 A AU2018346681 A AU 2018346681A AU 2018346681 B2 AU2018346681 B2 AU 2018346681B2
Authority
AU
Australia
Prior art keywords
cells
regulatory
seq
aspects
cell epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018346681A
Other languages
English (en)
Other versions
AU2018346681A1 (en
Inventor
William Martin
Amy S. Rosenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Food And Drug Administration
Epivax Inc
Original Assignee
Food And Drug Administration
Epivax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Food And Drug Administration, Epivax Inc filed Critical Food And Drug Administration
Publication of AU2018346681A1 publication Critical patent/AU2018346681A1/en
Application granted granted Critical
Publication of AU2018346681B2 publication Critical patent/AU2018346681B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2018346681A 2017-10-05 2018-10-05 Regulatory T cell epitopes Ceased AU2018346681B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762568625P 2017-10-05 2017-10-05
US201762568630P 2017-10-05 2017-10-05
US62/568,630 2017-10-05
US62/568,625 2017-10-05
US201862729792P 2018-09-11 2018-09-11
US62/729,792 2018-09-11
PCT/US2018/054595 WO2019071116A1 (en) 2017-10-05 2018-10-05 T REGULATORY LYMPHOCYTE EPITOPES

Publications (2)

Publication Number Publication Date
AU2018346681A1 AU2018346681A1 (en) 2020-04-16
AU2018346681B2 true AU2018346681B2 (en) 2024-02-22

Family

ID=65994377

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018346681A Ceased AU2018346681B2 (en) 2017-10-05 2018-10-05 Regulatory T cell epitopes

Country Status (6)

Country Link
US (2) US11441122B2 (enExample)
EP (1) EP3691673A4 (enExample)
JP (2) JP7274472B2 (enExample)
AU (1) AU2018346681B2 (enExample)
CA (1) CA3077084A1 (enExample)
WO (1) WO2019071116A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022011982A (es) * 2020-03-27 2022-12-15 Epivax Inc Epitopos de celulas t reguladoras.
JP2023520989A (ja) * 2020-03-27 2023-05-23 エピバックス・インコーポレーテッド １型糖尿病の予防および治療に有用なｔレジトープ構築物
CA3193819A1 (en) * 2020-09-25 2022-03-31 Anne De Groot Retro-inverso regulatory t cell epitopes
GB202100194D0 (en) * 2021-01-07 2021-02-24 Cambridge Entpr Ltd Inhibition of T-Cell activity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087161A1 (en) * 2002-04-18 2003-10-23 Merck Patent Gmbh Modified factor viii
US20040096456A1 (en) * 2000-12-01 2004-05-20 Conti-Fine Bianca M Method to treat hemophilia
US8586006B2 (en) * 2006-08-09 2013-11-19 Institute For Systems Biology Organ-specific proteins and methods of their use
WO2014145524A2 (en) * 2013-03-15 2014-09-18 Haplomics, Inc. Compositions and methods for immune tolerance induction to factor viii replacement therapies in subjects with hemophilia a

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP0815262A4 (en) 1995-03-24 2000-08-23 Scripps Research Inst Methods for identifying a factor v gene mutation
CA2500413A1 (en) * 2002-10-01 2004-04-15 Dnavec Research Inc. Method of strengthening foreign epitope presentation by mhc class i by inhibiting tap activity
EP1598367A1 (en) 2004-05-18 2005-11-23 ZLB Behring GmbH Modified coagulation factors with enhanced stability and their derivatives
CA2641519A1 (en) 2006-02-23 2007-09-07 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis using variant forms of activated factor v
ATE525392T1 (de) 2007-01-30 2011-10-15 Epivax Inc Regulatorische t-zellen-epitopen sowie zusammensetzungen damit und anwendungen davon
AU2012249553A1 (en) 2011-04-29 2013-10-24 Selecta Biociences, Inc. Tolerogenic synthetic nanocarriers for allergy therapy
AR101185A1 (es) 2014-07-11 2016-11-30 Novo Nordiks As Anticuerpos anti-factor v o factor v activado
WO2016178811A1 (en) * 2015-05-04 2016-11-10 Epivax, Inc. Modified h7 hemagluttinin glycoprotein of the influenza a/shanghai/2/2013 h7 sequence
WO2019210187A1 (en) 2018-04-26 2019-10-31 The University Of North Carolina At Chapel Hill Methods and compositions for treatment of hemophilia

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040096456A1 (en) * 2000-12-01 2004-05-20 Conti-Fine Bianca M Method to treat hemophilia
WO2003087161A1 (en) * 2002-04-18 2003-10-23 Merck Patent Gmbh Modified factor viii
US8586006B2 (en) * 2006-08-09 2013-11-19 Institute For Systems Biology Organ-specific proteins and methods of their use
WO2014145524A2 (en) * 2013-03-15 2014-09-18 Haplomics, Inc. Compositions and methods for immune tolerance induction to factor viii replacement therapies in subjects with hemophilia a

Also Published As

Publication number Publication date
JP2021503276A (ja) 2021-02-12
CA3077084A1 (en) 2019-04-11
US11441122B2 (en) 2022-09-13
US12275956B2 (en) 2025-04-15
US20200308542A1 (en) 2020-10-01
JP7274472B2 (ja) 2023-05-16
US20230212512A1 (en) 2023-07-06
WO2019071116A1 (en) 2019-04-11
AU2018346681A1 (en) 2020-04-16
JP2023106434A (ja) 2023-08-01
EP3691673A4 (en) 2021-06-09
EP3691673A1 (en) 2020-08-12

Similar Documents

Publication Publication Date Title
JP2024059975A (ja) 調節性ｔ細胞エピトープ、組成物およびその使用
US12275956B2 (en) Regulatory T cell epitopes
US20230279072A1 (en) Regulatory t cell epitopes
US11911414B2 (en) Regulatory T cell epitopes
US20230158165A1 (en) Tregitope constructs useful in the prevention and treatment of type 1 diabetes
US20230321237A1 (en) Regulatory t cell epitopes
US20240173377A1 (en) Retro - inverso regulatory t cell epitopes
HK40045381A (en) Regulatory t cell epitopes, compositions and uses thereof
HK1242342A1 (en) Regulatory t cell epitopes, compositions and uses thereof
JPWO2021195492A5 (enExample)
JPWO2022036193A5 (enExample)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired